7 results
Spectrum of activity for systemic antifungal agents
Antifungals: 5FC, flucytosine; AMB, amphotericin B; ANI, anidulafungin; CAS, caspofungin;
, flucytosine; AMB ... fluconazole; ISA ... Candida albicans ... , Candida krusei ... antibiogram #management #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... for Preventing ... 100 cells/mm3 g/mL ... Penicilliosis #IDSA ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... for Preventing ... if MIC<0.12 ug/ml ... Enteric #Bacterial #IDSA ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... suspension 4–6 mL ... #Candidiasis #candida ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
Here’s a review of the Renin-Angiotensin-Aldosterone system (RAAS)

This is a very common pathway that clinicians should
review of the Renin-Angiotensin-Aldosterone ... Antagonists), all ... increase potassium retention ... ReninAngiotensinAldosteroneSystem #RAAS #Pharmacology ... #Renin #Angiotensin
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
IDSA Recommendations ... for Preventing ... , 2 doses (0.5 mL ... #Zoster #VZV #IDSA ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... recommended for all ... Tuberculosis #TB #IDSA ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology